← 返回专利悬崖列表
盐酸噻加宾
Tier C · 观察 / 贸易Tiagabine Hydrochloride
Abbott Laboratories
原研
1996
首批上市
-
到期年（公开口径）
无销量数据
峰值销售
化学药
类型
靶点：GAT1
商品名：Tiabex、Gabitril
适应症（已批准）：癫痫、癫痫发作
各地区研发/上市状态
美国
批准上市
1997-09-30
欧盟
批准上市
1996-01-01
中国
临床三期
2014-04-02
日本
-
合成路线与中间体4 routes
原研路线 × 1优化路线（非专利）× 3工艺路线 × 0
路线按「原研路线 → 优化路线 / 工艺路线（非专利）」排序。每条路线附本站自绘的路线流程图（中间体 → 原料药）与中间体表（编号 / CAS / 英文名），可直接用于供应商开发与询价。流程图由本站依据已授权的结构化数据自行渲染，未使用任何第三方路线图。
原研Route 1步骤 7 · 总收率 5.60 g
TIAG-0015834-16-2TIAG-00214282-76-9TIAG-003148319-25-9TIAG-00430717-55-6TIAG-0054333-56-6TIAG-006148319-26-0TIAG-007109857-81-0TIAG-00825137-01-3TIAG-009145821-58-5TIAG-0102969-81-5API · 盐酸噻加宾
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| TIAG-001 | 5834-16-2 | 3-methylthiophene-2-carbaldehyde |
| TIAG-002 | 14282-76-9 | 2-bromo-3-methylthiophene |
| TIAG-003 | 148319-25-9 | bis(3-methylthiophen-2-yl)methanol |
| TIAG-004 | 30717-55-6 | bis(3-methylthiophen-2-yl)methanone |
| TIAG-005 | 4333-56-6 | bromocyclopropane |
| TIAG-006 | 148319-26-0 | cyclopropylbis(3-methylthiophen-2-yl)methanol |
| TIAG-007 | 109857-81-0 | 2,2'-(4-bromobut-1-ene-1,1-diyl)bis(3-methylthiophene) |
| TIAG-008 | 25137-01-3 | ethyl (R)-piperidine-3-carboxylate |
| TIAG-009 | 145821-58-5 | ethyl (R)-1-(4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl)piperidine-3-carboxylate |
| TIAG-010 | 2969-81-5 | ethyl 4-bromobutanoate |
优化Route 2步骤 7 · 总收率 28.00 g
TIAG-01153374-61-1TIAG-012—TIAG-013157925-13-8TIAG-014157925-14-9TIAG-015157925-15-0TIAG-016157925-16-1TIAG-017157925-17-2TIAG-0015834-16-2TIAG-0054333-56-6TIAG-00825137-01-3API · 盐酸噻加宾
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| TIAG-011 | 53374-61-1 | 2-bromo-5-chloro-3-methylthiophene |
| TIAG-012 | - | (5-chloro-3-methylthiophen-2-yl)(3-methylthiophen-2-yl)methanol |
| TIAG-013 | 157925-13-8 | (5-chloro-3-methylthiophen-2-yl)(3-methylthiophen-2-yl)methanone |
| TIAG-014 | 157925-14-9 | (5-methoxy-3-methylthiophen-2-yl)(3-methylthiophen-2-yl)methanone |
| TIAG-015 | 157925-15-0 | cyclopropyl(5-methoxy-3-methylthiophen-2-yl)(3-methylthiophen-2-yl)methanol |
| TIAG-016 | 157925-16-1 | (Z)-5-(4-bromo-1-(3-methylthiophen-2-yl)butylidene)-4-methylthiophen-2(5H)-one |
| TIAG-017 | 157925-17-2 | ethyl (R,Z)-1-(4-(3-methyl-5-oxothiophen-2(5H)-ylidene)-4-(3-methylthiophen-2-yl)butyl)piperidine-3-carboxylate |
| TIAG-001 | 5834-16-2 | 3-methylthiophene-2-carbaldehyde |
| TIAG-005 | 4333-56-6 | bromocyclopropane |
| TIAG-008 | 25137-01-3 | ethyl (R)-piperidine-3-carboxylate |
优化Route 3步骤 6 · 总收率 93.00 g
TIAG-00214282-76-9TIAG-01896-48-0TIAG-019847233-26-5TIAG-020847233-13-0TIAG-021495-19-2TIAG-0221499189-55-7TIAG-023148319-38-4TIAG-024—API · 盐酸噻加宾
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| TIAG-002 | 14282-76-9 | 2-bromo-3-methylthiophene |
| TIAG-018 | 96-48-0 | dihydrofuran-2(3H)-one |
| TIAG-019 | 847233-26-5 | 1,1-bis(3-methylthiophen-2-yl)butane-1,4-diol |
| TIAG-020 | 847233-13-0 | 4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl methanesulfonate |
| TIAG-021 | 495-19-2 | methyl 1,2,5,6-tetrahydropyridine-3-carboxylate |
| TIAG-022 | 1499189-55-7 | methyl 1-(4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl)-1,2,5,6-tetrahydropyridine-3-carboxylate |
| TIAG-023 | 148319-38-4 | 1-(4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid |
| TIAG-024 | - | - |
优化Route 4步骤 6 · 总收率 39.00 g
TIAG-00430717-55-6TIAG-00825137-01-3TIAG-009145821-58-5TIAG-02542843-94-7TIAG-0261417220-54-2TIAG-0271417220-55-3TIAG-0281417220-56-4TIAG-0291417220-57-5API · 盐酸噻加宾
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| TIAG-004 | 30717-55-6 | bis(3-methylthiophen-2-yl)methanone |
| TIAG-008 | 25137-01-3 | ethyl (R)-piperidine-3-carboxylate |
| TIAG-009 | 145821-58-5 | ethyl (R)-1-(4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl)piperidine-3-carboxylate |
| TIAG-025 | 42843-94-7 | ethyl 3-(bromotriphenyl-l5-phosphanyl)propanoate |
| TIAG-026 | 1417220-54-2 | ethyl 4,4-bis(3-methylthiophen-2-yl)but-3-enoate |
| TIAG-027 | 1417220-55-3 | 4,4-bis(3-methylthiophen-2-yl)but-3-enoic acid |
| TIAG-028 | 1417220-56-4 | 4,4-bis(3-methylthiophen-2-yl)but-3-enoyl chloride |
| TIAG-029 | 1417220-57-5 | ethyl (R)-1-(4,4-bis(3-methylthiophen-2-yl)but-3-enoyl)piperidine-3-carboxylate |
常见问题（FAQ）
盐酸噻加宾的适应症有哪些？
已批准的适应症包括：癫痫、癫痫发作。
盐酸噻加宾的专利什么时候到期？
盐酸噻加宾的专利到期年暂无公开口径，本页会在数据管道核实后更新。
盐酸噻加宾有几条合成路线？
本站收录 4 条合成路线，最短路线 6 步、总收率 93.00 g。每条路线的中间体均带登记编号与 CAS 号。
盐酸噻加宾的关键中间体在哪里可以采购？
盐酸噻加宾路线中的中间体均已建立 CAS 档案，可直接按 CAS 发起询价，需求会进入供应网络撮合池。
如何获取盐酸噻加宾中间体的报价？
在本页选择目标中间体的 CAS 进入档案页，或在询价页直接提交需求；CAS 会自动带入供需撮合流程，由供应网络反馈报价。
数据来源：多源数据交叉核实（仅结构化字段） · 2026-10-04